Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Operating Cash Flow
Cash generated by the company's core business operations during the period.
Prenetics Global LimitedNASDAQ: PRE
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns negative
Q1 FY2026 operating cash flow was -$12.12M, compared with $0 a year earlier. Trailing-twelve-month operating cash flow was -$33.94M.
Context
- Operating cash flow amounted to 23.6% of revenue in FY2025, down 70.7 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near -$12.12M or moves back toward the trailing-twelve-month quarterly average of -$8.48M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (21.81M) USD
- Year-over-year change
- +24.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.81M) | +24.5% |
| FY2024 | 2024-12-31 | (28.87M) | -109.8% |
| FY2023 | 2023-12-31 | (13.76M) | -194.8% |
| FY2022 | 2022-12-31 | 14.51M | +8.2% |
| FY2021 | 2021-12-31 | 13.42M | — |
Operating Cash Flow vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 operating cash flow of $33.94M is the 4th largest of the 11 companies compared; the peer median is $23.97M.
- Operating cash flow amounts to 29.8% of revenue for PRE, versus a peer median of 65.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $90.34M | +102.4% | -24.2% | 261.4% | |
| LTM Mar 2026 | $43.19M | -4887.7% | -89.9% | 38.2% | |
| LTM Mar 2026 | $38.79M | +43.8% | +14.6% | 205.6% | |
| LTM Mar 2026 | $33.94M | — | — | 29.8% | |
| LTM Mar 2026 | $28.17M | -10.5% | +32.5% | 87.2% | |
| LTM Mar 2026 | $23.97M | -30.6% | -7.4% | 810.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $23.97M | +5.4% | -21.3% | 1229.6% |
| LTM Mar 2026 | $19.99M | -42.0% | -17.7% | 44.5% | |
| LTM Mar 2026 | $18.73M | -66.2% | — | 24.0% | |
| LTM Mar 2026 | $12.8M | -64.4% | -12.8% | 8.4% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $4.4M | -26.5% | +6.3% | 1.0% |
| Peer median (excluding PRE) | $23.97M | -28.6% | -12.8% | 65.9% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.02M) | (190.45M) | (64.78M) | (49.81M) | (52.7M) |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| Deferred Income Tax | 3.73M | 7.15M | (385.84K) | (7.87M) | 0 |
| Stock-Based Compensation | 22.49M | 31.58M | 10.59M | 11.98M | 0 |
| Change in Working Capital | (6.59M) | (33.76M) | 24.21M | 1.97M | 6.62M |
| Accounts Receivables | (24.06M) | 6.97M | 37.63M | (428K) | (529K) |
| Inventory | (2.33M) | 1.26M | (1.73M) | 1.32M | (3.38M) |
| Accounts Payables | (3.46M) | (2.63M) | (5.62M) | (4.68M) | 4.91M |
| Other Working Capital | 23.26M | (39.36M) | (6.08M) | 5.75M | 5.62M |
| Other Non-Cash Items | 160.45M | 192.46M | 8.8M | 8.93M | 20.48M |
| Operating Cash Flow | 13.42M | 14.51M | (13.76M) | (28.87M) | (21.81M) |
| Capital Expenditures | (11.41M) | (6.34M) | (911.81K) | (1.07M) | (208K) |
| Acquisitions (Net) | 0 | (3.42M) | 0 | 21.65M | 37.78M |
| Purchases of Investments | (10M) | (39.92M) | (26M) | (129K) | (20M) |
| Sales of Investments | 0 | 3M | 19.92M | 16M | 0 |
| Other Investing Activities | (3.47M) | 531.99K | (76.52M) | 2.02M | 1,000K |
| Investing Cash Flow | (22.02M) | (46.14M) | (82.95M) | 38.54M | (35.79M) |
| Debt Repayment | (1.3M) | (1.88M) | (3.23M) | (2.56M) | 40.15M |
| Common Stock Issued | 0 | 116.86K | 2.17K | 0 | 2K |
| Common Stock Repurchased | 0 | (661.52K) | (1.23M) | (577K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.65M | 145.86M | (241.5K) | (203K) | (2.61M) |
| Financing Cash Flow | 29.32M | 143.32M | (4.7M) | (3.34M) | 37.54M |
| Effect of Forex Changes | 87.21K | (317.47K) | 467.93K | 221K | (65K) |
| Net Change in Cash | 20.8M | 111.37M | (100.95M) | 6.55M | (20.12M) |
| Free Cash Flow | 2M | 8.17M | (14.68M) | (29.94M) | (22.02M) |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.